Welcome to our dedicated page for Oncolytics Biotech Common Shares news (Ticker: ONCY), a resource for investors and traders seeking the latest updates and insights on Oncolytics Biotech Common Shares stock.
Oncolytics Biotech Inc. (symbol: ONCY) is a pioneering biotechnology company dedicated to the development of oncolytic viruses as innovative cancer therapeutics. Their flagship product, pelareorep, is a unique immunotherapeutic agent designed to harness the power of the human reovirus to enhance the body's immune response against cancer. Pelareorep has shown promising potential in making tumors more responsive to a variety of oncology treatments by promoting an inflamed tumor phenotype.
The company's robust clinical development pipeline includes multiple human trials targeting some of the most prevalent cancers, such as breast, gastrointestinal, and pancreatic cancers. Notably, Oncolytics is conducting a Phase III trial for head and neck cancers and has several ongoing trials in advanced stages, including the GOBLET study, which explores the efficacy of pelareorep in combination with different chemotherapy regimens.
In breast cancer, Oncolytics is advancing towards registration-enabling studies for HR+/HER2- metastatic breast cancer, supported by compelling data from the BRACELET-1 and IND-213 randomized studies. The company is also making significant strides in pancreatic cancer research, recently receiving a US$5 million grant from the Pancreatic Cancer Action Network (PanCAN) for a new Phase 1/2 cohort in the GOBLET study, assessing pelareorep in combination with modified FOLFIRINOX and atezolizumab (Tecentriq®).
Financially, Oncolytics is well-positioned with a strong balance sheet and ongoing support from strategic partnerships and grants. The company’s collaborations with leading research institutions and oncology networks enhance its clinical programs and accelerate the development of pelareorep as a versatile cancer therapy. Oncolytics continues to innovate and push the boundaries of cancer treatment, aiming to bring new hope to patients worldwide.
Oncolytics Biotech (NASDAQ: ONCY) has initiated the phase 1/2 GOBLET trial, dosing the first patient to evaluate the safety and efficacy of the combination of pelareorep and Roche's atezolizumab in gastrointestinal cancers, including metastatic pancreatic, colorectal, and anal cancers. The trial, managed by AIO in Germany, aims to improve patient responses to immune checkpoint inhibitors, addressing the high unmet need in gastrointestinal cancer treatments. The GOBLET study follows promising earlier results, which suggest significant clinical benefits in related conditions.
Oncolytics Biotech Inc. (NASDAQ: ONCY) will host a conference call on November 5, 2021, at 8:00 a.m. ET, to discuss third-quarter financial results and corporate updates. Investors can dial in North America at (888) 664-6383 or internationally at (416) 764-8650. The event will be webcast and archived on the company's Investor Relations page. Oncolytics is focused on developing pelareorep, an immunotherapeutic agent aimed at inducing immune responses against various cancers. The company is conducting clinical trials in combination with existing oncology treatments.
Oncolytics Biotech announced that its partner Adlai Nortye has begun dosing in a clinical trial in China, assessing the safety and efficacy of pelareorep-paclitaxel for advanced breast cancer. This bridging trial aims to enable data inclusion from North American studies in future regulatory submissions. Notably, previous trials indicated a significant survival benefit for patients using pelareorep in combination with paclitaxel. The ongoing collaboration aims to advance pelareorep towards registration in global markets, leveraging China's rapidly growing pharmaceutical landscape.
Oncolytics Biotech announced promising preclinical data highlighting the synergistic effects of pelareorep combined with radiotherapy. Presented at The International Conference on Immunotherapy Radiotherapy Combinations in Paris, the study demonstrated a significant increase in anti-cancer CD8+ T cells and improved survival rates in murine models. The pelareorep-radiotherapy combination outperformed single-agent therapies, indicating its potential for broader application across multiple cancer types. These findings advocate for further research into pelareorep as an effective cancer treatment.
Oncolytics Biotech reported significant progress in its clinical trials and financial health for Q2 2021. The AWARE-1 trial achieved its primary endpoint, showing that pelareorep synergizes with checkpoint inhibitors, enhancing survival metrics in breast cancer. Additionally, proof-of-concept data in metastatic pancreatic cancer indicates broad applicability across tumor types. The company maintains a strong financial position with $50.8 million in cash, supporting ongoing trials and strategic partnerships.
Oncolytics Biotech (NASDAQ: ONCY) announces its participation in the Canaccord Genuity 41st Annual Growth Conference, scheduled for August 10-12, 2021. Dr. Matt Coffey, CEO, will present on August 12 at 1:30 p.m. EDT. The event includes one-on-one investor meetings, and a live webcast will be available on Oncolytics' Investor Relations page, archived for 90 days. The company develops pelareorep, an immunotherapeutic agent aimed at treating various cancers by inducing immune responses. For more information, visit their website.
Oncolytics Biotech (NASDAQ: ONCY) will hold a conference call on August 6, 2021, at 8:00 a.m. ET to discuss the second quarter financial results and corporate updates. The call will be accessible via a toll-free number and will also be available through a webcast for three months. The biotechnology company is focused on developing pelareorep, an immunotherapeutic agent that induces anti-cancer immune responses. This agent is currently in clinical trials for various cancers, including a registration study in metastatic breast cancer.
Oncolytics Biotech Inc. (NASDAQ: ONCY) announced it will present at the Ladenburg Thalmann Healthcare Conference on July 14, 2021, at 4:30 PM Eastern Daylight Time. Dr. Matt Coffey, President & CEO, will lead the presentation. A live webcast will be available on the company's Investor Relations page and archived for 90 days. Oncolytics is developing pelareorep, an immunotherapeutic agent aimed at treating various cancers by inducing immune responses. The company is also engaging in one-on-one investor meetings during the conference.
Oncolytics Biotech (NASDAQ: ONCY) announced a promising clinical proof-of-concept for its pelareorep-checkpoint inhibitor combination therapy in pancreatic cancer. The phase 2 trial, featuring pembrolizumab (KEYTRUDA), showed a 42% disease control rate among patients who had progressed after first-line treatment. The results will be presented at the ASCO Annual Meeting in June 2021. Key findings highlight enhanced T cell activation and well-tolerated treatment. Oncolytics plans to further develop this therapy in collaboration with Roche through the GOBLET study.
Oncolytics Biotech Inc. (NASDAQ: ONCY) will participate in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on May 19, 2021, at 5:25 pm ET. Dr. Matt Coffey, President & CEO, will present, with a live webcast available on the company’s Investor Relations page. The conference runs from May 18-20, 2021, featuring one-on-one investor meetings. Oncolytics is developing pelareorep, an immuno-oncolytic virus aimed at treating various cancers, including in combination with checkpoint inhibitors. For more details, visit Oncolytics' website.
FAQ
What is the current stock price of Oncolytics Biotech Common Shares (ONCY)?
What is the market cap of Oncolytics Biotech Common Shares (ONCY)?
What is Oncolytics Biotech Inc. known for?
What cancers is Oncolytics currently targeting?
What is pelareorep?
What are the recent achievements of Oncolytics Biotech?
How is Oncolytics Biotech funded?
What is the GOBLET study?
What are the potential benefits of pelareorep?
What is the focus of Oncolytics' current clinical trials?
What partnerships does Oncolytics Biotech have?
Where can I find more information about Oncolytics Biotech?
